Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, March 31, 2023
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
[ Fri, Mar 31st 2023
] - WOPRAI
David Nierengarten Reiterated (STRO) at Buy and Held Target at $20 on, Mar 31st, 2023
David Nierengarten of Wedbush, Reiterated "Sutro Biopharma, Inc." (STRO) at Buy and Held Target at $20 on, Mar 31st, 2023.
David has made no other calls on STRO in the last 4 months.
There are 2 other peers that have a rating on STRO. Out of the 2 peers that are also analyzing STRO, 0 agree with David's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with David
- Asthika Goonewardene of "Truist Securities" Maintained at Strong Buy with Increased Target to $25 on, Friday, January 13th, 2023
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $18 on, Tuesday, January 10th, 2023
